Precipio (NASDAQ:PRPO – Get Free Report) and InnovAge (NASDAQ:INNV – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
Valuation and Earnings
This table compares Precipio and InnovAge”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 1.68 | -$360,000.00 | ($0.64) | -35.17 |
| InnovAge | $989.71 million | 1.26 | -$2.54 million | ($0.02) | -458.15 |
Insider and Institutional Ownership
10.4% of Precipio shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 1.0% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Precipio has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
Profitability
This table compares Precipio and InnovAge’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -4.47% | -8.49% | -5.75% |
| InnovAge | -0.26% | -1.03% | -0.47% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Precipio and InnovAge, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| InnovAge | 2 | 1 | 1 | 0 | 1.75 |
InnovAge has a consensus target price of $10.50, suggesting a potential upside of 14.59%. Given InnovAge’s stronger consensus rating and higher probable upside, analysts clearly believe InnovAge is more favorable than Precipio.
Summary
InnovAge beats Precipio on 9 of the 14 factors compared between the two stocks.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About InnovAge
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
